About neratinib
Irreversible HER2 tyrosine kinase inhibitor
Used for
- Extended adjuvant treatment of early-stage HER2-positive breast cancer after trastuzumab-based therapy.
- With capecitabine for advanced or metastatic HER2-positive breast cancer after prior treatment.
Usual adult dose
Early breast cancer: 240 mg by mouth once daily with food for one year. Advanced disease: 240 mg once daily with capecitabine, on a 21-day cycle.
Common side effects
- Diarrhea, sometimes severe
- Nausea and vomiting
- Abdominal pain
- Rash and fatigue
Important warnings
- Diarrhea can cause dehydration; preventive antidiarrheal treatment is usually started with therapy.
- Can cause liver injury; liver tests are monitored during treatment.
- Can harm an unborn baby; effective contraception is needed during treatment and for one month afterward.
- Swallow tablets whole; do not crush, split, or chew.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for at least one month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least one month after the last dose.
Interactions
- Avoid proton-pump inhibitors; they can reduce neratinib absorption.
- H2 blockers and antacids require carefully timed doses.
- Strong CYP3A inhibitors may increase neratinib levels.
- Strong CYP3A inducers may reduce neratinib effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.